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UDP-D-xylose:proteoglycan core protein b-D-xylosyl-
transferase (EC 2.4.2.26) is the initial enzyme in the
biosynthesis of chondroitin sulfate and dermatan
sulfate proteoglycans in fibroblasts and chondrocytes.
Secretion of xylosyltransferase into the extracellular
space was determined in cultured human dermal
fibroblasts. A more than 6-fold accumulation of
xylosyltransferase activity in cell culture supernatant
was observed (day 1, 0.6 mU per 106 cells; day 9, 4.1 mU
per 106 cells); however, intracellular xylosyltransferase
activity remained at a constant level (0.4 mU per 106
cells). Exposure of human chondrocytes to colchicine
led to a 3-fold decreased level of xylosyltransferase and
chondroitin-6-sulfate concentration in cell culture.
Specific xylosyltransferase activity and chondroitin-6-
sulfate concentration decreased in a concentration-
dependent manner and in parallel in culture medium
and accumulated 5-fold in cell lysates indicating that
xylosyltransferase is secreted simultaneously into the
extracellular space with chondroitin sulfate proteo-
The term scleroderma summarizes a heterogeneousgroup of diseases, which comprise systemic sclerosis(SSc; scleroderma), localized scleroderma, and the so-called overlap syndromes. SSc is a chronic inflam-matory disease of the connective tissue characterized
by: (i) excessive accumulation of extracellular matrix in skin and
various internal organs; (ii) severe alterations in the microvascula-
ture; and (iii) prominent inflammatory and immunologic alterations
(for review see Krieg and Meurer, 1988; Perez and Kohn, 1993).
Severity of the sclerotic processes and other clinical features are the
basis for the clinical classification of patients with SSc (LeRoy et al,
1988; Perez and Kohn, 1993).
Sclerotic processes led to a massive deposition of collagen fibrils
in skin and other organs and to an elevation of proteoglycan
metabolism in sclerotic organs (Kitabatake et al, 1983). Cultured
Manuscript received April 9, 1998; revised January 25, 1999; accepted
for publication February 17, 1999.
Reprint requests to: Knut Kleesiek, Institut fu¨r Laboratoriums-und
Transfusionsmedizin, Herz-und Diabeteszentrum Nordrhein-Westfalen,
Universita¨tsklinik der Ruhr-Universita¨t Bochum, Georgstraße 11, 32545
Bad Oeynhausen, Germany.
Abbreviations: SSc, systemic sclerosis; XT, xylosyltransferase.
0022-202X/99/$14.00 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
919
glycans. Xylosyltransferase activities were determined
in serum samples of 30 patients with systemic sclerosis.
Xylosyltransferase activities in female (mean value
1.28 mU per liter, 90% range 1.10–1.55 mU per liter)
and male patients (mean 1.39 mU per liter, 90% range
1.16–1.57 mU per liter) with systemic sclerosis were
significantly increased in comparison with blood
donors of a corresponding age. Furthermore, xylosyl-
transferase activity was correlated with the clinical
classification of systemic sclerosis. Female patients
with diffuse cutaneous systemic sclerosis showed
higher serum xylosyltransferase activities than patients
with limited systemic sclerosis. These results confirm
that the increase of proteoglycan biosynthesis in
sclerotic processes of scleroderma is closely related to
an elevated xylosyltransferase activity in blood and
demonstrate the validity of xylosyltransferase as an
additional diagnostic marker for determination of
sclerotic activity in systemic sclerosis. Key words:
chondroitin sulfate proteoglycan/systemic sclerosis/xylosyl-
transferase. J Invest Dermatol 112:919–924, 1999
dermal fibroblasts from patients with SSc have been shown to
synthesize collagen at an increased rate and to accumulate multiple
amounts of glycosaminoglycans in comparison with normal skin
fibroblasts (LeRoy, 1974; Bashey et al, 1984). Electron microscopy
investigations revealed that collagen fibrils in normal skin are
anchored by proteoglycans (Maeda et al, 1981). Decorin and
biglycan are small proteoglycans containing chondroitin and derma-
tan sulfate chains. They have been shown to interact specifically
with type I collagen fibrils and other components of the extracellular
matrix on the surface of cultured human fibroblasts (Schmidt et al,
1987; Kresse et al, 1994). In vitro, recombinant biglycan and decorin
are potential inhibitors of fibrillogenesis of types I and II collagen
(Vogel et al, 1984; Vogel and Trotter, 1987).
These findings indicate the importance of proteoglycan and
glycosaminoglycan synthesis for the metabolism of collagen fibrils.
Increased amounts of glycosaminoglycans have been found in
patients with SSc (Ishikawa and Horiuchi, 1975; Tajima et al, 1982)
and in cultured fibroblasts isolated from scleroderma patients (Cabral
and Castor, 1983; Bashey et al, 1984). In skin biopsies of patients
suffering from SSc an elevated chondroitin sulfate and dermatan
sulfate concentration was found, indicating their role in fibrosis
(Tajima et al, 1982; Akimoto et al, 1992). Further investigations
showed that the increased chondroitin sulfate and dermatan sulfate
glycosaminoglycan content in the affected skin correlates with the
severity of sclerotic skin (Higushi et al, 1994).
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Chondroitin sulfate and dermatan sulfate are bound to the
proteoglycan core protein by a xylose–galactose–galactose binding
region (Kjellen and Lindahl, 1991). UDP-D-xylose:proteoglycan
core protein β-D-xylosyltransferase (EC 2.4.2.26, XT) is the chain-
initiating enzyme involved in the biosynthesis of glycosaminoglycan
containing proteoglycans (Schwartz, 1977; Kearns et al, 1991). The
enzyme catalyzes the transfer of D-xylose from UDP-D-xylose to
specific serine residues of the core protein and is a regulatory factor
in chondroitin sulfate biosynthesis (Rode´n, 1980). The XT is
present in the cisternae of the rough endoplasmatic reticulum of
various species (Hoffmann et al, 1984). XT from bovine chondro-
cytes was shown to be secreted simultaneously from the endo-
plasmatic reticulum into the extracellular space with chondroitin
sulfate proteoglycans (Ka¨hnert et al, 1991). Therefore, the increased
biosynthesis and secretion of dermatan sulfate and chondroitin
sulfate proteoglycans during sclerosis is suspected to result in
elevated levels of XT in the affected organs and in blood.
XT activities in the synovial fluid were found to be significantly
increased in chronic inflammatory joint diseases (Kleesiek et al,
1987). The determination of XT activity in serum, however,
showed no significant differences due to the insensitivity of the
used XT assay with silk fibroin as acceptor. Meanwhile we
developed a sensitive XT assay using recombinant bikunin, the
inhibitory component of the inter-α-trypsin-inhibitor, as substrate
(Weilke et al, 1997). With this assay we are able to determine small
changes of XT activity in blood reliably.
In our study we investigated XT activities in cultured human
dermal fibroblasts and the secretion of XT and chondroitin-
6-sulfate into the extracellular space by human chondrocytes.
Furthermore, we determined XT activities in serum of patients
with SSc in order to evaluate the validity of XT as a diagnostic
marker for fibrotic alterations of skin and internal organs during
these diseases.
MATERIALS AND METHODS
Materials UDP-[14C]-D-xylose (9.88 kBq per nmol) was purchased from
DuPont (Bad Homburg, Germany) and 25 mm diameter nitrocellulose
discs from Sartorius (Go¨ttingen, Germany). Scintillation mixture and the
liquid scintillation counter LS500TD were supplied by Beckman (Fullerton,
CA) and Microcon 3000 ultrafiltration tubes by Amicon (Beverly, MA).
Serum monovettes were purchased from Sarstedt (Nu¨mbrecht, Germany).
Heat-inactivated fetal calf serum, trypsin/ethylenediamine tetraacetic
acid solution, antibiotic/antimycotic solution, L-glutamine, Dulbecco’s
phosphate-buffered saline, Trypan Blue, 425–600 µm glass beads, colchi-
cine, RPMI1640 cell culture medium, and the Bicinchoninic Acid Protein
Assay Kit were obtained from Sigma (Deisenhofen, Germany). Cell culture
flasks, serological pipettes, and sterile tubes were provided by Becton
Dickinson (Heidelberg, Germany) and human albumin solution by Centeon
Pharma (Marburg, Germany). Twenty-four well plates were purchased
from Nunc (Wiesbaden, Germany). Human adult dermal fibroblasts and
fibroblast growth medium FGM-2 were obtained from Biowhittaker
(Walkersville, MD). The Super G analyzer was supplied by RLT (Mo¨hnesee,
Germany) and the ACA analyzer by Dade Behring Diagnostica (Mu¨nchen,
Germany).
The ANA Profil ELISA was purchased from Elias (Freiburg, Germany)
and anti-dsDNA radioimmunoassay from DPC Biermann (Bad Nauheim,
Germany). The Quantafluor HEp2-cell line substrate immunofluorescence
assay and mouse stomach/kidney slides were provided by Sanofi Diagnostics
Pasteur (Chaska, MN). Freka-Fluor Borrelia IgG IFT/IFA assay was obtained
from Fresenius (Bad Homburg, Germany) and Borrelia burgdorferi IgG/IgM
western blot from Autoimmun Diagnostika (Straβberg, Germany).
All other chemicals in pro analysi quality were obtained from Merck
(Darmstadt, Germany).
Synthesis of recombinant bikunin Recombinant bikunin was
expressed in Escherichia coli strain BL21(DE3) as described previously
(Brinkmann et al, 1997).
Determination of XT activity The method for determination of XT
activity is based on the incorporation of [14C]-D-xylose with recombinant
bikunin as acceptor and is published elsewhere in detail (Weilke et al,
1997). The reaction mixture for the assay contained in a total volume of
100 µl/50 µl of XT solution, 25 mM 4-morpholine-ethanesulfonic acid
(pH 6.5), 25 mM KCl, 5 mM KF, 5 mM MgCl2, 5 mM MnCl2,
1.0 µM UDP-[14C]-D-xylose, and 1.5 µM recombinant bikunin. Following
incubation for 1 h at 37°C, the reaction mixtures were placed on
nitrocellulose discs. After drying, the discs were washed for 10 min with
100 g per liter trichloroacetic acid and three times with 50 g per liter
trichloroacetic acid solution. Incorporated radioactivity was quantitated by
liquid scintillation counting. The enzyme activity was expressed in units
(1 unit 5 1 µmol of incorporated xylose per min).
Quantitation of chondroitin-6-sulfate Chondroitin-6-sulfate concen-
trations in cell lysates and cell culture medium were determined with a
competitive enzyme immunoassay using biotinylated chondroitin-6-sulfate
antigen as described before (Ka¨hnert et al, 1994).
Cell culture Human chondrocytes from sternal cartilage obtained during
open heart surgery were prepared as described previously (Brinkmann et al,
1997). Cells were grown in 24 well plates with RPMI1640 medium
supplemented with antibiotic/antimycotic solution, 2 mM L-glutamine
and 10% heat-inactivated fetal calf serum at 37°C in a humidified atmosphere
(95% air and 5% CO2) using standard procedures (Butler and Dawson,
1992). Glucose and lactate concentrations of the cell culture media were
monitored using the Super G and the ACA analyzers, respectively. After
the cells reached confluence the medium was changed to RPMI1640
without fetal calf serum for 2 d. The cell culture medium was then changed
to serum-free RPMI1640 supplemented with colchicine. After 24 h the
medium was harvested and stored at –20°C after centrifugation at 1000 3 g
for 10 min. For quantification of intracellular XT activities cells were
detached and mechanically lysed as described. All experiments were
performed in triplicates.
Human adult dermal fibroblasts were cultivated in FGM-2 according to
the supplier’s instructions. After the cells reached 80% of confluence the
medium was changed and intracellular and secreted XT activities were
measured for a period of 9 d. XT activity in the spent medium was
determined after harvesting and centrifugation at 1000 3 g for 10 min.
Intracellular XT activity was determined after detachment and lysis of
the cells.
Preparation of cell lysates Cells were mechanically lysed in order to
quantify intracellular XT activity. Cells were detached using trypsin/
ethylenediamine tetraacetic acid solution, centrifuged at 1000 3 g for
10 min and then gently washed twice with Dulbecco’s phosphate-buffered
saline supplemented with 1% human albumin and 0.1% Tween20. The
number of viable cells was determined using Trypan Blue exclusion. Glass
beads (425–600 µm) were added and the samples were vigorously shaken
on a vortex mixer for 2 min followed by 10 min incubation on ice. This
procedure was repeated twice and the degree of lysis was optically
controlled. Samples were then centrifuged at 1000 3 g for 10 min and
the supernatant was stored at –20°C.
Determination of total protein concentration Total protein concen-
trations in cell culture supernatant and cell lysates were determined using
the Bicinchoninic Acid Protein Assay Kit. Free amino acids in the samples
were removed prior to protein determination by ultrafiltration with
Microcon 3000 tubes according to the manufacturer’s instructions.
Collection of serum samples Venous blood samples were collected in
serum monovettes. After clotting and centrifugation at 4000 3 g for 15 min
the serum was stored at –70°C until assayed. Samples were collected from
male (n 5 150) and female (n 5 165) blood donors, aged 20–65 y. To
determinate XT activities in serum of patients with scleroderma specimens
were collected from 24 female and six male patients with SSc.
Detection of auto-antibodies Anti-nuclear antibodies in serum of
patients with scleroderma were quantitated using the immunofluorescence
assay Quantafluor HEp2-cell line substrate. Identification of different auto-
antibodies in patient serum samples was performed with commercially
available assays. The specimens were investigated for presence of the
following auto-antibodies: anti-U-1-RNP, anti-U1-ribonucleoprotein;
anti-RNP/SM, anti-ribonucleoprotein particle; anti-Sm, anti-RNAse, and
Sm-antigen protein complex; anti-SS-A (Ro), anti-Sjo¨gren-syndrome-A
antigen; anti-SS-B (La), anti-Sjo¨gren-syndrome-B; anti-Scl70, anti-DNA
topoisomerase I; anti-CENP, anti-centromer antigen; anti-PmScl, anti-
PmScl protein complex; anti-JO1, anti-histidyl-tRNA-synthetase; AMA,
anti-mitochondrial antibodies; ASMA, anti-smooth muscle antibodies.
Differentiation of auto-antibodies against extractable nuclear antigens
was performed with the ANA Profil ELISA. Anti-mitochondrial and anti-
smooth muscle antibodies were determined by immunofluorescence with
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Table I. Clinical characteristics of the SSc patients studied
Patient Clinical Raynaud’s Organs Skin ANAc XT activity
no. Sex Age classification phenomenon affecteda scoreb (IFT) ENAd (mU per liter)
1 M 59 limited 1 S 5 1280 anti-Scl-70 1.07
2 M 61 limited 1 S, L, GI, A 2560 anti-Scl-70 1.76
3 M 69 limited – S, L, GI, K 2560 negative 1.55
4 M 57 limited 1 S, L 4 320 negative 1.35
5 M 66 limited – S, L, A 0 160 anti-PmScl 1.09
6 M 58 diffuse 1 S, L, A 9 1280 negative 1.53
7 F 46 limited 1 S, L 1280 anti-SS-A (Ro); anti-SS-B (La) 1.15
8 F 55 limited 1 S, L, GI 640 anti-Scl-70 1.39
9 F 56 limited 1 S, L 320 negative 1.40
10 F 59 limited 1 S, K 640 anti-Scl-70 1.31
11 F 64 limited 1 S, K, GI 1280 anti-Scl-70 1.20
12 F 79 limited 1 S, L 640 anti-SS-A (Ro); anti-Scl-70 1.53
13 F 72 limited 1 S, L, GI 1280 negative 1.34
14 F 56 limited 1 S, GI 640 anti-SS-A (Ro); anti-SS-B (La); anti-CENP 1.14
15 F 31 limited 1 S 80 anti-PmScl 1.06
16 F 44 limited 1 S 5120 anti-CENP 0.96
17 F 55 limited 1 S 320 anti-CENP 1.37
18 F 59 limited 1 S, L 640 anti-U1-RNP 1.14
19 F 65 limited 1 S 4 5120 anti-CENP 1.51
20 F 68 limited 1 S 4 2560 negative 1.12
21 F 72 limited 1 S, L 3 5120 anti-CENP 1.55
22 F 72 limited – S 2 5120 negative 1.12
23 F 78 limited 1 S, GI 1 640 anti-CENP 1.10
24 F 80 limited 1 S, K, L 5120 anti-CENP 1.16
25 F 82 limited 1 S, K 2560 anti-PmScl 1.05
26 F 32 diffuse 1 S, L 10 320 negative 1.24
27 F 46 diffuse 1 S, L, H, A, GI 10 5120 anti-Scl-70 1.31
28 F 57 diffuse 1 S 6 5120 negative 1.46
29 F 57 diffuse 1 S, A 6 5120 anti-Scl-70 1.57
30 F 68 diffuse 1 S ,40 negative 1.52
aS, skin; L, lung; K, kidneys; A, joints; H, heart; GI, gastrointestinum.
bSkin scores were determined using a modified Rodnan skin thickness score.
cAnti-nuclear antibodies (ANA) were quantitated as immunofluorescence titer (IFT; normal range, , 40).
dThe following auto-antibodies against extractable nuclear antigens (ENA) were detected in the investigated sera: anti-CENP, anti-centromer antigen; anti-Scl70, anti-
DNA topoisomerase I; anti-SS-A (Ro), anti-Sjo¨gren syndrome A antigen; anti-SS-B (La), anti-Sjo¨gren syndrome B antigen; anti-PmScl, anti-PMScl protein complex; anti-
U1-RNP, anti-U1 ribonucleoprotein particle.
mouse stomach/kidney slides and antibodies directed against double-
stranded DNA by anti-dsDNA radioimmunoassay. IgG antibodies against
Borrelia burgdorferi were detected using the Freka-Fluor Borrelia IgG IFT/
IFA assay and the Borrelia burgdorferi IgG/IgM western blot. All tests were
performed according to the manufacturers’ instructions.
Determination of skin score values in scleroderma patients The
skin score representing the numerical severity grade at a specific number
of skin sites was determined using a modified Rodnan skin thickness score
(Silman et al, 1995). The modified Rodnan skin score was determined
using the 0–3 scale (0, normal skin; 1, thickened; 2, unable to pinch; 3,
unable to move) at eight distinct sites: upper arms, forearms, dorsum of
hands, fingers, thighs, lower legs, dorsum of feet, and regio pectoralis.
The evaluation of the skin score was always performed by the same
investigator (C.H.).
Characteristics of patients studied In our study we investigated 24
female and six male patients with SSc (Table I). All fulfilled the American
College of Rheumatology (formerly, the American Rheumatism Associ-
ation) criteria for the classification of SSc (Subcommittee for Scleroderma
Criteria of the American Rheumatism Association Diagnostic and Thera-
peutic Criteria Committee 1980). Five women, aged 32–57, were suffering
from the diffuse form of SSc and 19 female patients, aged 31–82, from
limited SSc. One male patient with the diffuse form and five men with
limited SSc were investigated. The classification of systemic scleroderma
in the two subtypes (limited and diffuse disease) was done according to
LeRoy et al (1988). In all patients studied the skin was affected by
sclerotic processes. Elevated immunofluorescence titers against anti-nuclear
antibodies were observed in 96% of women and in 100% of men. The
predominant autoantibodies were found to be anti-DNA topoisomerase I
(anti-Scl70) and anti-centromer antigen (anti-CENP). Skin score values
were determined in 13 of the patients studied using a modified Rodnan
skin thickness score (Silman et al, 1995) (Table I).
Statistical analysis Statistical analysis was performed using the t-test
and Kolmogoroff–Smirnoff test. Correlation and regression analysis was
performed using Pearsson’s correlation coefficient and analysis of variance
(ANOVA) including the F-test. p ø 0.05 were considered significant.
RESULTS
Human dermal fibroblasts secrete XT into the extracellular
space XT activities in cell lysates and in cell culture supernatant
obtained from cultured human dermal fibroblasts were analyzed
over a period of 9 d (Fig 1). Mean XT activities in cell lysates
representing the intracellular amount of XT were 0.36 µU per 106
cells (SD 0.23). No increase of intracellular XT activity was
observed during the 9 d incubation period; however, we found an
accumulation of XT activities in cell culture supernatant. After
incubation for 7–9 d XT activities in harvested culture medium
were 11-fold higher than in cell lysates. The mean values of secreted
XT in cell culture supernatant after 7–9 d were calculated as 3.89–
4.06 µU per 106 cells (SD 0.35–0.51) (Fig 1).
Colchicine inhibits secretion of XT in human chondrocytes
In order to clarify whether the release of XT into the extracellular
space is due to a secretion process and whether it is linked to the
secretion of chondroitin sulfate proteoglycans we exposed cultured
human sternal cartilage chondrocytes to the secretion blocking
agent colchicine. After 24 h XT activities and chondroitin-6-sulfate
concentrations in cell culture medium and cell lysates were measured
(Fig 2). Exposure of cultured chondrocytes to colchicine led to a
3–5-fold decreased level of total XT activity and total chondroitin-
6-sulfate concentration in the cell culture. XT activity and
chondroitin-6-sulfate concentration decreased in a concentration-
dependent manner and in parallel in the spent medium and
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Figure 1. XT is secreted by human adult dermal fibroblasts. XT
activities in cell culture supernatant and cell lysates of cultured human
dermal fibroblasts are shown. Cells were grown until they reached 80% of
confluence and XT activities in culture medium and in cell lysates were
determined for a period of 9 d. XT secreted into the extracellular space is
represented by open boxes whereas intracellular XT is indicated by filled
circles. Mean values and the corresponding SD are shown.
Figure 2. Colchicine inhibits secretion of XT and chondroitin-6-
sulfate proteoglycans in cultured human chondrocytes. Chondroitin-
6-sulfate concentrations and specific XT activities were determined in
cultured human sternal cartilage chondrocytes after exposure to colchicine
for 24 h. (A) XT activity (u) and chondroitin-6-sulfate concentration (d)
in the harvested cell culture supernatant representing the amount of
the enzyme and the polysaccharide secreted into the extracellular space.
(B) Corresponding enzyme activity and chondroitin-6-sulfate concentration
in cell lysates representing the intracellular amount of XT and of the
measured glycosaminoglycan. Mean values and SD are shown. Values are
averages of the analysis of three cultures.
accumulated 4–5-fold in cell lysates. The ratio of extracellular to
intracellular XT activity changed from 350:1 in the control group
to 20:1 after exposure to 10 µmol per liter colchicine for 24 h.
Figure 3. Elevated serum XT activities in patients with SSc. XT
activities in serum of male patients with SSc (n 5 6), aged 57–69, and of
healthy blood donors (n 5 150), 55–65 y old. In women with SSc
(n 5 24), mean XT activities were 1.5-fold increased in comparison with
20–65 y old female blood donors (n 5 165). Mean values and 90% ranges
are shown.
XT activity is elevated in serum of scleroderma patients We
determined XT activities in serum samples of 30 patients suffering
from SSc. XT activities in female patients with SSc (n 5 24), aged
31–82 y, were significantly elevated in comparison with female
blood donors (n 5 165), 20–65 y old (Fig 3). In serum specimens
of women with SSc the mean value and 90% range were 1.28 mU
per liter (SD 0.18) and 1.10–1.55 mU per liter. In female blood
donors the mean value and 90% range were 0.89 mU per liter (SD
0.20) and 0.6–1.1 mU per liter. XT activities in serum of male
patients with SSc (n 5 6), 57–69 y old, were calculated as 1.39 mU
per liter and 1.16–1.57 mU per liter. In the corresponding blood
donor control group (n 5 150), aged 55–65, mean XT activities
of 0.98 mU per liter were measured. The 90% range was determined
as 0.72–1.21 mU per liter.
Serum XT activities in diffuse and limited forms of SSc We
analyzed the determined XT activities referring to the clinical
classification of the sclerotic disease. In women with diffuse forms
of SSc (n 5 5) mean serum XT activities were increased in
comparison with patients with limited SSc (n 5 19). Mean values
and 90% ranges were 1.42 mU per liter (SD 0.14) and 1.31–
1.55 mU per liter in diffuse forms and 1.24 mU per liter (SD 0.18)
and 1.05–1.53 mU per liter in limited SSc (Fig 4). In men with
limited cutaneous SSc (n 5 5) serum XT activities were 1.07–
1.76 mU per liter (mean value 1.36 mU per liter; SD 0.29) and in
the male patient with diffuse SSc (n 5 1) XT activity was
determined as 1.53 mU per liter. A significant correlation of XT
activities and clinical classification could not be proven due to the
limited number of patients investigated in our study.
Correlation of serum XT activity with skin scores XT
activities in serum of five female patients with limited SSc and in
four women with diffuse SSc were compared with the clinical skin
scores (Table I). No significant correlation of serum XT activities
and skin score values was found.
Serum XT activities in SSc patients remain elevated in
longitudinal studies We investigated the longitudinal alterations
of serum XT activities in 12 SSc patients. Three male and nine
female patients suffering from SSc were re-examined after 1 y. The
skin score remained constant during this period as well as the XT
activity. Neither a major increase nor decrease of serum XT activity
values was observed. Serum XT activities were differing less than
6 11% in comparison with the enzyme activities determined 1 y
before (Table II).
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Figure 4. XT activities in serum of female patients with SSc. Mean
values in serum of women with diffuse SSc and of female patients with
limited SSc and XT activities of each patient are given. The striped box
indicates the 90% range of serum XT activities of normal blood donors.
DISCUSSION
The degree and activity of sclerosis are important parameters for
the clinical classification of SSc (LeRoy et al, 1988). An elevation
of dermatan sulfate and chondroitin sulfate concentrations in skin
biopsies was shown to correlate with the severity of skin involved
(Higushi et al, 1994). Biosynthesis of these glycosaminoglycans is
initiated by XT, which is secreted into extracellular space by
cultured dermal fibroblasts (Fig 1). The observed effects of the
exposure of human chondrocytes to colchicine demonstrate that
XT and chondroitin-6-sulfate proteoglycans are simultaneously
secreted into the culture medium (Fig 2). Therefore, an increase
in dermatan sulfate and chondroitin sulfate biosynthesis in SSc
should result in an elevation of XT activity. Using our new sensitive
XT assay with recombinant bikunin as substrate (Weilke et al,
1997) we found increased levels of XT activity in the serum of
patients suffering from diseases associated with fibrotic processes,
e.g., hepatitis C virus induced liver fibrosis and lung fibrosis
(unpublished observations). This XT assay is suitable for the
determination of low XT activities in blood (lower detection limit
0.02 mU per liter) and therefore, enables the detection of small
changes in the enzyme activity (Weilke et al, 1997).
Determination of XT activities in dermal fibroblast culture
revealed a secretion of XT into extracellular space shown by the
accumulation of XT activity in the cell culture supernatant during
the incubation period (Fig 1). After 7 d more than 90% of the
total XT activity was found to be located in the culture medium
whereas the intracellular amount of XT remained at a constant
level. Similar results were observed in cultured human chondrocytes
(Fig 2). In order to elucidate whether XT is released autonomously
into culture medium or whether it is attached to proteoglycans we
investigated the effect of the secretion blocking agent colchicine
on human chondrocytes. Experiments were performed with
chondrocytes as they secrete large amounts of chondroitin sulfate
proteoglycans, whereas the major secretory products of human skin
fibroblasts is a 110 kDa proteodermatan sulfate (Glo¨ssl et al, 1984).
Colchicine inhibits the microtubule-mediated release of chondroitin
sulfate into the extracellular matrix (Kim and Conrad, 1980).
Exposure of sternal cartilage chondrocytes to colchicine resulted in
a concentration-dependent decrease in XT activity and chondroitin-
6-sulfate concentration in the extracellular space (Fig 2); however,
Table II. Serum XT activities in SSc patients remain
elevated in longitudinal studies
Serum XT activity (mU per liter)
Patienta Initial value Value after 1 y Alteration
Men 1.07 1.18 19%
1.53 1.56 12%
1.09 1.06 23%









aPatients were re-examined after 12 mo. The serum XT activity was determined
and compared with the initial value. The differences between both values are given
in percentage. No significant alterations of skin score values were observed during
the 1 y period.
a 5-fold accumulation of enzyme activity and chondroitin sulfate
concentration in the cells was observed. Colchicine was shown not
to influence total protein synthesis (Rennison et al, 1992; Evangelisti
et al, 1995). Therefore, our results show that XT is secreted
simultaneously into the extracellular matrix with chondroitin sulfate
containing proteoglycans. Evangelisti et al (1995) have demonstrated
that the effect of colchicine on the secretion of sulfated glycosamino-
glycans in cultured skin fibroblasts is comparable with that in
human chondrocytes. This lets us conclude that an elevation of
dermatan and chondroitin sulfate biosynthesis during the sclerotic
process in scleroderma may result in an increased secretion of XT.
Future experiments on XT secretion in fibroblasts from SSc patients
may reveal differences in XT expression in comparison with normal
control fibroblasts. It remains to be elucidated, however, whether
in vitro studies using cultured SSc fibroblasts are suitable to simulate
complex inflammatory and fibrotic processes. Further detailed
studies using immunologic staining may yield information on the
colocalization and secretion of proteoglycans and XT as soon as
anti-XT antibodies are available.
Significantly elevated XT activities were observed in the serum
of patients with SSc. Mean values were increased 1.4–1.5 times in
comparison with blood donors of corresponding age groups (Fig 3).
Analysis of serum XT activities in blood donors revealed an age
and sex dependence (Weilke et al, 1997). Therefore, in our
experiment the control groups were of the same age and sex as the
scleroderma patients. We suggest that the increase in serum XT
activity observed is a direct consequence of the elevated proteo-
glycan biosynthesis in the fibrotic skin and organ systems. An
elevation of dermatan sulfate and chondroitin sulfate concentrations
in fibrotic skin has been shown by a diversity of authors
(Fleischmajer and Perlish, 1972; Bashey et al, 1984; Juhlin et al,
1986; Higushi et al, 1994). As XT is the initial enzyme involved
in the synthesis of dermatan sulfate, heparan sulfate, and chondroitin
sulfate proteoglycans, an increased level of XT is an inevitable
prerequisite for rapid synthesis of proteoglycans. Our cell culture
experiments have demonstrated that XT is secreted into the
extracellular space together with chondroitin sulfate proteoglycans,
where it is attached to the core protein of the proteoglycan (Fig 2).
Therefore, we conclude that the elevation of XT activities observed
in serum samples of scleroderma patients is a direct consequence
of the increased proteoglycan biosynthesis in sclerotic organ systems
and not due to a release from the destroyed tissue during the
inflammatory process.
Regarding the clinical classification of the investigated specimens
we found increased serum XT activities in female patients with
the diffuse form of SSc in comparison with women with limited
SSc (Fig 4). Diffuse SSc was clinically characterized by a more
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rapid and severe progression of fibrotic processes in skin and inner
organs than limited SSc. Higushi et al (1994) proposed a nexus
between sclerotic alterations and the glycosaminoglycan content in
skin. Our results indicate that elevated serum XT activities occur
due to the larger number of affected organs and the accelerated
fibrotic processes in patients with diffuse cutaneous SSc.
Our longitudinal studies have shown that XT activities in serum
samples of SSc patients remain at an increased level with alterations
of less than 11% over a period of 1 y (Table II). During this
period, however, no significant changes of extent and severity of
sclerotic lesions have been observed. The high XT activities
observed in the serum of patients suffering from SSc can either be
a consequence of an elevated biosynthesis of XT, an increased
release of XT from fibroblasts during sclerotic processes or a
reduced rate of degradation of the enzyme. As data on the half-
life of XT in blood are not yet available a decreased rate of
degradation cannot be excluded. An elevated release of XT from
destroyed cartilage tissue was observed in the synovial fluid during
chronic inflammatory joint diseases (Kleesiek et al, 1987). An
increased biosynthesis of XT during sclerotic processes could be
demonstrated using northern blot analysis of mRNA encoding XT.
As information on the nucleotide sequence of the enzyme is not
yet available detailed studies on mRNA levels for XT will have to
be performed in the future. The increased amounts of dermatan
sulfate and chondroitin sulfate in skin biopsies from scleroderma
patients and the simultaneous secretion of XT and chondroitin-6-
sulfate proteoglycans into the extracellular space, however, let us
conclude that an increased rate of biosynthesis of XT is the reason
for the high XT activities in the serum of patients with SSc.
SSc is characterized by fibrotic alterations of parenchymal and
connective tissue. These inflammatory processes are accompanied
by excessive accumulation of collagen fibrils and proteoglycans in
the extracellular matrix of skin and other organ systems. The
resulting increased rate of proteoglycan biosynthesis reflects the
activity of the sclerotic process. As XT is the initial enzyme
involved in the biosynthesis of glycosaminoglycan chains, elevated
XT activity is more a measure for an actually increased rate of
proteoglycan synthesis than for the total amount of proteoglycans
in the involved organ systems. Therefore, XT is a marker of disease
activity in SSc, whereas the determination of the skin score reflects
the disease severity.
In our study, no significant correlation of XT activity in blood
and skin score values in female SSc patients was observed. These
findings are in accordance with the fact that a pronounced disease
severity does not necessarily imply an elevated sclerotic activity.
Patients with extended sclerosis might show a reduced sclerotic
activity as soon as the fibrotic alterations of the organs involved
are finished. This final condition of the sclerotic process then results
in a diminishing biosynthesis of proteoglycans and collagen fibrils.
As XT is a measure for the actual rate of proteoglycan synthesis
the extended disease severity might not necessarily result in elevated
XT activities in these SSc patients.
Our results show that the increase of XT in blood is closely
related to sclerotic processes in patients with scleroderma and
demonstrate that this enzyme is an adequate diagnostic marker
suitable for the determination of sclerotic activity in SSc.
We would like to thank Anne-Kathrin Vollmer for technical assistance and Grainne
Delany for linguistic advice.
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